NUCALA / 新可来
国药准字SJ20210030 · 注射剂
Re-registration deadline: 2031-02-28
The certificate expires 2031-08-31. Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew is filed no later than 6 months before expiry.
| Approval number (批准文号) | 国药准字SJ20210030 |
|---|---|
| Generic name (通用名) | Mepolizumab Injection 美泊利珠单抗注射液 |
| Marketing Authorisation Holder (上市许可持有人) | GlaxoSmithKline Trading Services Limited Ireland |
| Certificate valid until (有效期至) | 2031-08-31 |
| Re-registration deadline, Art. 82 (法定申报时限) | 2031-02-28 |
| Data as of (数据快照日) | 2026-09-10 |
All China registrations held by GlaxoSmithKline Trading Services Limited →
Check another product →Every figure above is taken from the public NMPA overseas-drug database (境外生产药品库) as of 2026-09-10, or computed from it under Art. 82. Registration data changes; the NMPA portal governs. This page states no view on whether this product’s Domestic Responsible Person (境内责任人) arrangement meets NMPA Announcement No. 137 — that cannot be determined from a single public entry.